A phase I/IIa open-label study to assess the safety, tolerability and preliminary efficacy of AT7519M, a selective small molecule inhibitor of cyclin dependent kinases, in patients with refractory hematological malignancies

Trial Profile

A phase I/IIa open-label study to assess the safety, tolerability and preliminary efficacy of AT7519M, a selective small molecule inhibitor of cyclin dependent kinases, in patients with refractory hematological malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2006

At a glance

  • Drugs AT 7519 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Lymphoma; Metaplasia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top